Condensed Consolidated Statements of Shareholders' Equity (Deficit) and Comprehensive Income (Loss) (Unaudited) (USD $)	Predecessor	Predecessor Common Stock	Predecessor Common Stock Gemini [Member]	Predecessor Common Stock AFH [Member]	Predecessor Additional Paid-in Capital	Predecessor Additional Paid-in Capital Gemini [Member]	Predecessor Additional Paid-in Capital AFH [Member]	Predecessor Treasury Stock	Predecessor Accumulated Other Comprehensive Income	Predecessor Accumulated Deficit During Development Stage	Predecessor Noncontrolling Interest	Predecessor Series A Preferred Stock	Predecessor Series B Preferred Stock	Successor	Successor Common Stock	Successor Subscription Receivable	Successor Additional Paid-in Capital	Successor Accumulated Deficit During Development Stage	Successor Noncontrolling Interest	Successor Series A Preferred Stock	Successor Series A Preferred Stock Common Stock	Successor Series A Preferred Stock Additional Paid-in Capital
Beginning Balance (Pre-Adjusted Balance)
Cancellation of Predecessor common stock and fresh start adjustments	$ (124,495,151)	$ (42,820)			$ (150,426,331)			$ 25,974,000
Cancellation of Predecessor accumulated deficit and accumulated other comprehensive loss	128,335,806
Cancellation of Predecessor common stock and fresh start adjustment, shares		(42,820,380)						(4,000,000)
Issuance of common stock in connection with emergence from Chapter 11	5,472,000	11,400			5,460,600
Issuance of common stock in connection with emergence from Chapter 11, shares		11,400,000
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(115,322,121)
Net income (loss)	(117,121,644)
Ending Balance (Pre-Adjusted Balance)	(11,146,504)	42,820			142,737,500			(25,974,000)		(128,335,806)	382,982
Ending Balance at Aug. 31, 2009	(7,305,849)				(7,688,831)
Ending Balance, Shares (Pre-Adjusted Balance)		42,820,380						4,000,000
Beginning Balance (Pre-Adjusted Balance)
Issuance of common & preferred stock for cash/services (December 28, 1995)	820	2,285			(1,465)
Issuance of common & preferred stock for cash/services (November 07, 1996)	50,000	11			49,989
Issuance of common & preferred stock for cash/services (November 29, 1996)	10,000	2			9,998
Issuance of common & preferred stock for cash/services (December 19, 1996)	30,000	7			29,993
Issuance of common & preferred stock for cash/services (December 26, 1996)	50,000	11			49,989
Issuance of common & preferred stock for cash/services, shares (December 28, 1995)		2,285,291
Issuance of common & preferred stock for cash/services, shares (November 07, 1996)		11,149
Issuance of common & preferred stock for cash/services, shares (November 29, 1996)		2,230
Issuance of common & preferred stock for cash/services, shares (December 19, 1996)		6,690
Issuance of common & preferred stock for cash/services, shares (December 26, 1996)		11,148
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(270,468)									(270,468)
Ending Balance at Dec. 31, 1996	(129,648)	2,316			138,504					(270,468)
Ending Balance, Shares at Dec. 31, 1996		2,316,508
Issuance of common & preferred stock for cash/services (December 27, 1997)	95,000	21			94,979
Issuance of common & preferred stock for cash/services (September 01, 1997)	36,260	11			36,249
Issuance of common & preferred stock for cash/services (December 28, 1997)	10,255	287			9,968
Issuance of common & preferred stock for cash/services, shares (December 27, 1997)		21,182
Issuance of common & preferred stock for cash/services, shares (September 01, 1997)		11,148
Issuance of common & preferred stock for cash/services, shares (December 28, 1997)		287,193
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(52,550)									(52,550)
Ending Balance at Dec. 31, 1997	(40,683)	2,635			279,700					(323,018)
Ending Balance, Shares at Dec. 31, 1997		2,636,031
Issuance of common & preferred stock for cash/services (August 23, 1998)	20,067	4			20,063
Issuance of common & preferred stock for cash/services, shares (August 23, 1998)		4,459
Repurchase of common/treasury stock (September 29, 1998)	(50,280)							(50,280)
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(195,675)									(195,675)
Ending Balance at Dec. 31, 1998	(266,571)	2,639			299,763			(50,280)		(518,693)
Ending Balance, Shares at Dec. 31, 1998		2,640,490						2,400
Issuance of common & preferred stock for cash/services (September 10, 1999)	150,000	53			149,947
Issuance of common & preferred stock for cash/services, shares (September 10, 1999)		52,506
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(1,306,778)									(1,306,778)
Ending Balance at Dec. 31, 1999	(1,423,349)	2,692			449,710			(50,280)		(1,825,471)
Ending Balance, Shares at Dec. 31, 1999		2,692,996						2,400
Issuance of common & preferred stock for cash/services (January 18, 2000)	1,923	54			1,869
Issuance of common & preferred stock for cash/services (March 01, 2000)	25	69			(44)
Issuance of common & preferred stock for cash/services (April 04, 2000)	10	28			(18)
Issuance of common & preferred stock for cash/services, shares (January 18, 2000)		53,583
Issuance of common & preferred stock for cash/services, shares (March 01, 2000)		68,698
Issuance of common & preferred stock for cash/services, shares (April 04, 2000)		27,768
Repurchase of common stock/treasury, shares (September 29, 1998)								2,400
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(807,076)									(807,076)
Ending Balance at Dec. 31, 2000	(2,228,467)	2,843			451,517			(50,280)		(2,632,547)
Ending Balance, Shares at Dec. 31, 2000		2,843,045						2,400
Issuance of common & preferred stock for cash/services (July 01, 2001)	56	157			(101)
Issuance of common & preferred stock for cash/services (July 01, 2001 (b))	45	125			(80)
Issuance of common & preferred stock for cash/services (August 10, 2001)	2,020,000	1,347			2,018,653
Issuance of common & preferred stock for cash/services (August 10, 2001 (b))	60	60
Issuance of common & preferred stock for cash/services (August 28, 2001)	40,000	27			39,973
Issuance of common & preferred stock for cash/services (September 30, 2001)	471,555	314			471,241
Issuance of common & preferred stock for cash/services (November 01, 2001)	218,900	146			218,754
Issuance of common & preferred stock for cash/services, shares (July 01, 2001)		156,960
Issuance of common & preferred stock for cash/services, shares (July 01, 2001 (b))		125,000
Issuance of common & preferred stock for cash/services, shares (August 10, 2001)		1,346,669
Issuance of common & preferred stock for cash/services, shares (August 10, 2001 (b))		60,000
Issuance of common & preferred stock for cash/services, shares (August 28, 2001)		26,667
Issuance of common & preferred stock for cash/services, shares (September 30, 2001)		314,370
Issuance of common & preferred stock for cash/services, shares (November 01, 2001)		145,933
Issuance of common stock for capitalization of accrued salaries (August 10, 2001)	328,125	70			328,055
Issuance of common stock for capitalization of accrued salaries, shares (August 10, 2001)		70,000
Issuance of common stock for conversion of convertible securities (August 10, 2001)	1,611,346	1,750			1,609,596
Issuance of common stock for conversion of convertible securities, shares (August 10, 2001)		1,750,000
Issuance of common stock for conversion of convertible shareholder notes payable (August 10, 2001)	135,667	209			135,458
Issuance of common stock for conversion of convertible shareholder notes payable, shares (August 10, 2001)		208,972
Issuance of common stock for bridge financing (August 10, 2001)	108	300			(192)
Issuance of common stock for bridge financing, shares (August 10, 2001)		300,000
Retirement of treasury stock (August 10, 2001)					(50,280)			50,280
Retirement of treasury stock, shares (August 10, 2001)								(2,400)
Issuance of common stock for net assets/acquisition (August 10, 2001)			3,942	3,900		(3,942)	(3,900)
Issuance of common stock for net assets/acquisition, shares (August 10, 2001)			3,942,400	3,899,547
Transaction and fund raising expenses (August 10, 2001)	(48,547)				(48,547)
Uncompensated contribution of services (3rd Quarter)	55,556				55,556
Uncompensated contribution of services (4th Quarter)	100,000				100,000
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(1,652,004)									(1,652,004)
Ending Balance at Dec. 31, 2001	1,052,400	15,190			5,321,761					(4,284,551)
Ending Balance, Shares at Dec. 31, 2001		15,189,563
Issuance of common & preferred stock for cash/services					502,517					(502,661)		144
Issuance of common & preferred stock for cash/services (April 26, 2002)	2,818,236				2,817,331							905
Issuance of common & preferred stock for cash/services (May 16, 2002)	2,773,129				2,772,239							890
Issuance of common & preferred stock for cash/services (May 31, 2002)	2,474,175				2,473,380							795
Issuance of common & preferred stock for cash/services (June 28, 2002)	713,221				712,991							230
Issuance of common & preferred stock for cash/services (July 15, 2002)	233,961				233,886							75
Issuance of common & preferred stock for cash/services (August 01, 2002)	57,600	38			57,562
Issuance of common & preferred stock for cash/services, shares												143,507
Issuance of common & preferred stock for cash/services, shares (April 26, 2002)												905,000
Issuance of common & preferred stock for cash/services, shares (May 16, 2002)												890,250
Issuance of common & preferred stock for cash/services, shares (May 31, 2002)												795,000
Issuance of common & preferred stock for cash/services, shares (June 28, 2002)												229,642
Issuance of common & preferred stock for cash/services, shares (July 15, 2002)												75,108
Issuance of common & preferred stock for cash/services, shares (August 01, 2002)		38,400
Uncompensated contribution of services (1st Quarter)					100,000
Uncompensated contribution of services (2nd Quarter)	100,000				100,000
Uncompensated contribution of services (3rd Quarter)	100,000				100,000
Uncompensated contribution of services (4th Quarter)	100,000				100,000
Issuance of warrants for services (September 06, 2002)	103,388				103,388
Deemed dividend associated with beneficial conversion of preferred stock					10,178,944					(10,178,944)
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(5,433,055)									(5,433,055)
Other comprehensive income, foreign currency translation adjustment	13,875								13,875
Comprehensive income (loss)	(5,419,180)
Ending Balance at Dec. 31, 2002	5,206,930	15,228			25,573,999				13,875	(20,399,211)		3,039
Ending Balance, Shares at Dec. 31, 2002		15,227,963										3,038,507
Issuance of common & preferred stock for cash/services	(1,087,200)									(1,087,200)
Issuance of common & preferred stock for cash/services (January 07, 2003)	92,400	62			92,338
Issuance of common & preferred stock for cash/services (May 09, 2003)	2,773,328				2,773,218								110
Issuance of common & preferred stock for cash/services (May 16, 2003)	1,145,750				1,145,704								46
Issuance of common & preferred stock for cash/services (August 27, 2003)	18,455,561	3,359			18,452,202
Issuance of common & preferred stock for cash/services (3rd Quarter)	310,000	202			309,798
Issuance of common & preferred stock for cash/services (4th Quarter)	279,500	137			279,363
Issuance of common & preferred stock for cash/services, shares (January 07, 2003)		61,600
Issuance of common & preferred stock for cash/services, shares (May 09, 2003)													110,250
Issuance of common & preferred stock for cash/services, shares (May 16, 2003)													45,500
Issuance of common & preferred stock for cash/services, shares (August 27, 2003)		3,359,331
Issuance of common & preferred stock for cash/services, shares (3rd Quarter)		202,500
Issuance of common & preferred stock for cash/services, shares (4th Quarter)		136,500
Issuance of common stock for conversion of convertible securities (2nd Quarter)	40,701	147			40,626							(72)
Issuance of common stock for conversion of convertible securities (3rd Quarter)	(78,809)	7,189			(82,875)							(2,967)	(156)
Issuance of common stock for conversion of convertible securities, shares (2nd Quarter)		147,062										(70,954)
Issuance of common stock for conversion of convertible securities, shares (3rd Quarter)		7,188,793										(2,967,553)	(155,750)
Issuance of common stock for conversion of convertible securities, shares (4th Quarter)		393
Issuance of common stock for net assets/acquisition (March 31, 2003)	540,000	100			539,900
Issuance of common stock for net assets/acquisition, shares (March 31, 2003)		100,000
Uncompensated contribution of services (1st Quarter)	100,000				100,000
Uncompensated contribution of services (2nd Quarter)	100,000				100,000
Deemed dividend associated with beneficial conversion of preferred stock					1,244,880					(1,244,880)
Cancellation/Retirement of common/restricted stock (March 31, 2003)	(119,459)	(79)			(119,380)
Cancellation/Retirement of common/restricted stock, shares (March 31, 2003)		(79,382)
Conversion of warrant into common stock (2nd Quarter)		114			(114)
Conversion of warrant into common stock (3rd Quarter)		213			(213)
Conversion of warrants in to common stock, shares (2nd Quarter)		114,598
Conversion of warrants in to common stock, shares (3rd Quarter)		212,834
Compensation expense on options and warrants issued to non-employees and directors	412,812				412,812
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(11,268,294)									(11,268,294)
Other comprehensive income, foreign currency translation adjustment	360,505								360,505
Comprehensive income (loss)	(10,907,789)
Ending Balance at Dec. 31, 2003	17,263,725	26,672			50,862,258				374,380	(33,999,585)
Ending Balance, Shares at Dec. 31, 2003		26,672,192
Issuance of common & preferred stock for cash/services (2nd Quarter)	56,817,434	7,200			56,810,234
Issuance of common & preferred stock for cash/services, shares (2nd Quarter)		7,200,000
Repurchase of common/treasury stock (4th Quarter)	25,974,000							25,974,000
Repurchase of common stock/treasury, shares (4th Quarter)								4,000,000
Conversion of warrant into common stock (1st Quarter)		79			(79)
Conversion of warrants in to common stock, shares (1st Quarter)		78,526
Compensation expense on options and warrants issued to non-employees and directors (1st Quarter)	1,410,498	1,410,498
Compensation expense on options and warrants issued to non-employees and directors (2nd Quarter)	143,462				143,462
Compensation expense on options and warrants issued to non-employees and directors (3rd Quarter)	229,133				229,133
Compensation expense on options and warrants issued to non-employees and directors (4th Quarter)	127,497				127,497
Issuance of common stock for cash in connection with exercise of stock options (1st Quarter)	95,000	15			94,985
Issuance of common stock for cash in connection with exercise of stock options (2nd Quarter)		52			(52)
Issuance of common stock for cash in connection with exercise of stock options (3rd Quarter)	190,000	110			189,890
Issuance of common stock for cash in connection with exercise of stock options, shares (1st Quarter)		15,000
Issuance of common stock for cash in connection with exercise of stock options, shares (2nd Quarter)		51,828
Issuance of common stock for cash in connection with exercise of stock options, shares (3rd Quarter)		110,000
Issuance of common stock in connection with exercise of warrants (1st Quarter)	7,720	4			7,716
Issuance of common stock in connection with exercise of warrants (3rd Quarter)		7			(7)
Issuance of common stock in connection with exercise of warrants (4th Quarter)		28			(28)
Issuance of common stock in connection with exercise of warrants, shares (1st Quarter)		4,000
Issuance of common stock in connection with exercise of warrants, shares (3rd Quarter)		7,431
Issuance of common stock in connection with exercise of warrants, shares (4th Quarter)		27,652
Issuance of common stock for cash in connection with exercise of warrants (3rd Quarter)	59,695	28			59,667
Issuance of common stock for cash in connection with exercise of warrants, shares (3rd Quarter)		28,270
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(21,474,469)									(21,474,469)
Other comprehensive income, foreign currency translation adjustment	79,725								79,725
Other comprehensive income, net unrealized gain on available-for-sale investments	10,005								10,005
Comprehensive income (loss)	(21,384,739)
Ending Balance at Dec. 31, 2004	28,985,425	34,195			109,935,174			(25,974,000)	464,110	(55,474,054)
Ending Balance, Shares at Dec. 31, 2004		34,194,899						4,000,000
Conversion of warrant into common stock (2nd Quarter)	(28)	28
Conversion of warrant into common stock (3rd Quarter)		12			(12)
Conversion of warrants in to common stock, shares (2nd Quarter)		27,785
Conversion of warrants in to common stock, shares (3rd Quarter)		12,605
Compensation expense on options and warrants issued to non-employees and directors (1st Quarter)	33,565				33,565
Compensation expense on options and warrants issued to non-employees and directors (2nd Quarter)	(61,762)				(61,762)
Compensation expense on options and warrants issued to non-employees and directors (3rd Quarter)	(137,187)				(137,187)
Compensation expense on options and warrants issued to non-employees and directors (4th Quarter)	18,844				18,844
Issuance of common stock for cash in connection with exercise of stock options (1st Quarter)	75,000	25			74,975
Issuance of common stock for cash in connection with exercise of stock options, shares (1st Quarter)		25,000
Compensation expense on acceleration of options (4th Quarter)	14,950				14,950
Compensation expense on restricted stock award issued to employee (4th Quarter)	606				606
Conversion of predecessor company shares		94
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders	(35,777,584)									(35,777,584)
Other comprehensive income, foreign currency translation adjustment	(1,372,600)								(1,372,600)
Foreign exchange gain on substantial liquidation of foreign entity	133,851								133,851
Other comprehensive income, net unrealized gain on available-for-sale investments	(10,005)								(10,005)
Comprehensive income (loss)	(37,026,338)
Ending Balance at Dec. 31, 2005	(8,096,897)	34,260			109,879,125			(25,974,000)	(784,644)	(91,251,638)
Ending Balance, Shares at Dec. 31, 2005		34,260,383						4,000,000
Compensation expense on options and warrants issued to non-employees and directors (1st Quarter)	42,810				42,810
Compensation expense on options and warrants issued to non-employees and directors (2nd Quarter)	96,177				96,177
Compensation expense on options and warrants issued to non-employees and directors (3rd Quarter)	25,627				25,627
Compensation expense on options and warrants issued to non-employees and directors (4th Quarter)	34,772				34,772
Issuance of common stock for cash in connection with exercise of stock options (2nd Quarter)	16,500	10			16,490
Issuance of common stock for cash in connection with exercise of stock options (3rd Quarter)	156,900	76			156,824
Issuance of common stock for cash in connection with exercise of stock options, shares (2nd Quarter)		10,000
Issuance of common stock for cash in connection with exercise of stock options, shares (3rd Quarter)		76,000
Compensation expense on option awards issued to employees/directors/consultants (1st Quarter)	46,336				46,336
Compensation expense on option awards issued to employees/directors/consultants (2nd Quarter)	407,012				407,012
Compensation expense on option awards issued to employees/directors/consultants (3rd Quarter)	389,458				389,458
Compensation expense on option awards issued to employees/directors/consultants (4th Quarter)	390,547				390,547
Compensation expense on restricted stock issued to employees (1st Quarter)	23,497	129			23,368
Compensation expense on restricted stock issued to employees (2nd Quarter)	4,210				4,210
Compensation expense on restricted stock issued to employees (3rd Quarter)	3,605				3,605
Compensation expense on restricted stock issued to employees (4th Quarter)	88				88
Compensation expense on restricted stock issued to employees, shares (1st Quarter)		128,750
Cancellation of unvested restricted stock (2nd Quarter)		(97)			97
Cancellation of unvested restricted stock (4th Quarter)		(15)			15
Cancellation of unvested restricted stock, shares (2nd Quarter)		(97,400)
Cancellation of unvested restricted stock, shares (4th Quarter)		(15,002)
Acquisition of Agera	2,182,505										2,182,505
Comprehensive income (loss):
Net income (loss)	(35,899,538)									(35,821,406)	(78,132)
Other comprehensive income, foreign currency translation adjustment	657,182								657,182
Comprehensive income (loss)	(35,242,356)
Ending Balance at Dec. 31, 2006	(39,519,209)	34,363			111,516,561			(25,974,000)	(127,462)	(127,073,044)	2,104,373
Ending Balance, Shares at Dec. 31, 2006		34,362,731						4,000,000
Issuance of common & preferred stock for cash/services (3rd Quarter)	13,752,167	6,767			13,745,400
Issuance of common & preferred stock for cash/services, shares (3rd Quarter)		6,767,647
Compensation expense on options and warrants issued to non-employees and directors (1st Quarter)	39,742				39,742
Compensation expense on options and warrants issued to non-employees and directors (2nd Quarter)	39,981				39,981
Issuance of common stock for cash in connection with exercise of stock options (1st Quarter)	23,100	15			23,085
Issuance of common stock for cash in connection with exercise of stock options (3rd Quarter)	3,166	2			3,164
Issuance of common stock for cash in connection with exercise of stock options, shares (1st Quarter)		15,000
Issuance of common stock for cash in connection with exercise of stock options, shares (3rd Quarter)		1,666
Issuance of common stock in connection with exercise of warrants (3rd Quarter)	894,304	493			893,811
Issuance of common stock in connection with exercise of warrants, shares (3rd Quarter)		492,613
Compensation expense on option awards issued to employees/directors/consultants (1st Quarter)	448,067				448,067
Compensation expense on option awards issued to employees/directors/consultants (2nd Quarter)	462,363				462,363
Compensation expense on option awards issued to employees/directors/consultants (3rd Quarter)	478,795				478,795
Compensation expense on option awards issued to employees/directors/consultants (4th Quarter)	378,827				378,827
Compensation expense on restricted stock issued to employees (1st Quarter)	88				88
Compensation expense on restricted stock issued to employees (2nd Quarter)	88				88
Compensation expense on restricted stock issued to employees (3rd Quarter)	88				88
Compensation expense on restricted stock issued to employees (4th Quarter)	88				88
Expense in connection with modification of employee stock options (1st Quarter)	1,178,483				1,178,483
Comprehensive income (loss):
Net income (loss)	(35,819,461)									(35,573,114)	(246,347)
Other comprehensive income, foreign currency translation adjustment	846,388								846,388
Comprehensive income (loss)	(34,973,073)
Ending Balance at Dec. 31, 2007	(56,792,935)	41,640			129,208,631			(25,974,000)	718,926	(162,646,158)	1,858,026
Ending Balance, Shares at Dec. 31, 2007		41,639,657						4,000,000
Cancellation/Retirement of common/restricted stock	(1)	(1)
Cancellation/Retirement of common/restricted stock, shares		(165)
Compensation expense on option awards issued to employees/directors/consultants (1st Quarter)	151,305				151,305
Compensation expense on option awards issued to employees/directors/consultants (2nd Quarter)	193,754				193,754
Compensation expense on option awards issued to employees/directors/consultants (3rd Quarter)	171,012				171,012
Compensation expense on option awards issued to employees/directors/consultants (4th Quarter)	166,196				166,196
Expense in connection with modification of employee stock options (1st Quarter)	1,262,815				1,262,815
Compensation expense on option awards issued to non-employees (1st Quarter)	44,849				44,849
Compensation expense on option awards issued to non-employees (2nd Quarter)	62,697				62,697
Compensation expense on option awards issued to non-employees (3rd Quarter)	166,687				166,687
Compensation expense on option awards issued to non-employees (4th Quarter)	(86,719)				(86,719)
Comprehensive income (loss):
Net income (loss)	(33,091,855)									(31,411,179)	(1,680,676)
Reclassification of foreign exchange gain on substantial liquidation of foreign entities	(2,152,569)								(2,152,569)
Other comprehensive income, foreign currency translation adjustment	1,433,643								1,433,643
Comprehensive income (loss)	(33,810,781)
Ending Balance at Dec. 31, 2008	(88,471,121)	41,639			131,341,227			(25,974,000)		(194,057,337)	177,350
Ending Balance, Shares at Dec. 31, 2008		41,639,492						4,000,000
Issuance of common stock for conversion of convertible securities (1st Quarter)	344,000	38			343,962
Issuance of common stock for conversion of convertible securities (2nd Quarter)	10,470,000	1,143			10,468,857
Issuance of common stock for conversion of convertible securities, shares (1st Quarter)		37,564
Issuance of common stock for conversion of convertible securities, shares (2nd Quarter)		1,143,324
Compensation expense on option awards issued to employees/directors/consultants (Two Months Ended August 31, 2009)	35,382				35,382
Compensation expense on option awards issued to employees/directors/consultants (1st Quarter)	138,798				138,798
Compensation expense on option awards issued to employees/directors/consultants (2nd Quarter)	112,616				112,616
Compensation expense on option awards issued to non-employees (1st Quarter)	1,746				1,746
Balance of expense due to cancellation of options issued to employees and directors in bankruptcy (Two Months Ended August 31, 2009)	294,912				294,912
Cancellation of Predecessor common stock and fresh start adjustments	(124,495,151)	(42,820)			(150,426,331)			25,974,000
Cancellation of Predecessor accumulated deficit and accumulated other comprehensive loss	128,335,806									128,335,806
Cancellation of Predecessor common stock and fresh start adjustment, shares		(42,820,380)						(4,000,000)
Issuance of common stock in connection with emergence from Chapter 11	5,472,000	11,400			5,460,600
Issuance of common stock in connection with emergence from Chapter 11, shares		11,400,000
Comprehensive income (loss):
Net income (loss)	65,927,163									65,721,531	205,632
Comprehensive income (loss)	65,927,163
Ending Balance (Pre-Adjusted Balance)	(11,146,504)	42,820			142,737,500			(25,974,000)		(128,335,806)	382,982
Ending Balance at Aug. 31, 2009	(7,305,849)				(7,688,831)						382,982			(1,833,849)	11,400		(2,228,231)		382,982
Ending Balance, Shares (Pre-Adjusted Balance)		42,820,380						4,000,000
Beginning Balance, Shares at Aug. 31, 2009															11,400,000
Issuance of common & preferred stock for cash/services (October 28, 2009)														58,652	25		58,627
Issuance of common & preferred stock for cash/services, shares (October 28, 2009)															25,501
Compensation expense on option awards issued to employees/directors/consultants														326,838			326,838
Compensation expense on option awards issued to non-employees														386,380			386,380
Issuance of 2.7 million shares of common stock in connection with the exit financing														1,800,000	2,667		1,797,333
Issuance of 2.7 million shares of common stock in connection with the exit financing, shares															2,666,666
Compensation expense on shares issued to management														168,000	600		167,400
Compensation expense on shares issued to management, shares															600,000
Comprehensive income (loss):
Net income (loss)														(5,034,506)				(5,049,999)	15,493
Comprehensive income (loss)														(5,034,506)
Ending Balance at Dec. 31, 2009														(4,128,485)	14,692		508,347	(5,049,999)	398,475
Ending Balance, Shares at Dec. 31, 2009															14,692,167
Beginning Balance (Pre-Adjusted Balance)	(11,146,504)	42,820			142,737,500			(25,974,000)		(128,335,806)	382,982
Beginning Balance at Aug. 31, 2009					(7,688,831)									(1,833,849)
Beginning Balance, Shares (Pre-Adjusted Balance)		42,820,380						4,000,000
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders														(38,275,135)
Net income (loss)														(38,167,001)
Ending Balance at Sep. 30, 2011														3,202,727
Ending Balance at Sep. 30, 2011														3,693,843	95,278	(2,038,733)	43,421,317
Ending Balance, Shares at Sep. 30, 2011															95,278,255
Beginning Balance at Dec. 31, 2009														(4,128,485)
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders														(8,281,245)
Net income (loss)														(8,243,998)
Ending Balance (Pre-Adjusted Balance)
Beginning Balance at Dec. 31, 2009														(4,128,485)	14,692		508,347	(5,049,999)	398,475
Beginning Balance, Shares at Dec. 31, 2009															14,692,167
Issuance of common & preferred stock for cash/services														3,469,400	5,077		3,464,323			364,000	607	363,393
Issuance of common & preferred stock for cash/services, shares															5,076,664						606,667
Issuance of warrants for services														(2,890,711)			(2,890,711)
Compensation expense on option awards issued to employees/directors/consultants (1st Quarter)														324,377			324,377
Compensation expense on option awards issued to employees/directors/consultants (2nd Quarter)														222,011			222,011
Compensation expense on option awards issued to employees/directors/consultants (3rd Quarter)														183,231			183,231
Compensation expense on option awards issued to employees/directors/consultants (4th Quarter)														104,094			104,094
Compensation expense on option awards issued to non-employees (1st Quarter)														18,391			18,391
Compensation expense on option awards issued to non-employees (2nd Quarter)														33,206			33,206
Compensation expense on option awards issued to non-employees (3rd Quarter)														7,724			7,724
Compensation expense on option awards issued to non-employees (4th Quarter)														27,507			27,507
Compensation expense on shares issued to management (1st Quarter)														18,000			18,000
Compensation expense on shares issued to management (2nd Quarter)														18,000			18,000
Compensation expense on shares issued to management (3rd Quarter)														18,000			18,000
Compensation expense on shares issued to management (4th Quarter)														18,000			18,000
Comprehensive income (loss):
Net income (loss)														(12,879,633)				(12,931,531)	51,898
Comprehensive income (loss)														(12,879,633)
Ending Balance at Dec. 31, 2010														(15,523,261)
Ending Balance at Dec. 31, 2010														(15,072,888)	20,376		2,437,893	(17,981,530)	450,373
Ending Balance, Shares at Dec. 31, 2010															20,375,498
Issuance of common & preferred stock for cash/services (2nd Quarter)														1,580,560	1,909		1,578,651
Issuance of common & preferred stock for cash/services (3rd Quarter)														19,098,705	41,409	(2,038,733)	21,096,029
Issuance of common & preferred stock for cash/services, shares (2nd Quarter)															1,908,889
Issuance of common & preferred stock for cash/services, shares (3rd Quarter)															41,409,461
Conversion of warrant into common stock (1st Quarter)														327,813	3,894		323,919
Conversion of warrant into common stock (2nd Quarter)														4,558,322	11,554		4,546,768
Conversion of warrant into common stock (3rd Quarter)														3,554,064	7,480		3,546,584
Conversion of warrants in to common stock, shares (1st Quarter)															3,894,000
Conversion of warrants in to common stock, shares (2nd Quarter)															11,554,000
Conversion of warrants in to common stock, shares (3rd Quarter)															7,480,000
Issuance of common stock for cash in connection with exercise of stock options (2nd Quarter)															246		(246)
Issuance of common stock for cash in connection with exercise of stock options, shares (2nd Quarter)															246,141
Issuance of common stock in connection with exercise of warrants (1st Quarter)														241,831	289		241,542
Issuance of common stock in connection with exercise of warrants (2nd Quarter)														6,072,957	7,230		6,065,727
Issuance of common stock in connection with exercise of warrants (3rd Quarter)														945,376	891		944,485
Issuance of common stock in connection with exercise of warrants, shares (1st Quarter)															289,599
Issuance of common stock in connection with exercise of warrants, shares (2nd Quarter)															7,230,103
Issuance of common stock in connection with exercise of warrants, shares (3rd Quarter)															890,564
Compensation expense on option awards issued to employees/directors/consultants (1st Quarter)														995,551			995,551
Compensation expense on option awards issued to employees/directors/consultants (2nd Quarter)														1,082,503			1,082,503
Compensation expense on option awards issued to employees/directors/consultants (3rd Quarter)														225,235			225,235
Compensation expense on option awards issued to non-employees (1st Quarter)														38,203			38,203
Compensation expense on option awards issued to non-employees (2nd Quarter)														250,473			250,473
Compensation expense on shares issued to management (1st Quarter)														18,000			18,000
Compensation expense on shares issued to management (2nd Quarter)														18,000			18,000
Compensation expense on shares issued to management (3rd Quarter)														12,000			12,000
Comprehensive income (loss):
Net loss attributable to Fibrocell Science, Inc. common shareholders														(20,293,605)
Net income (loss)														(20,252,862)				(20,293,605)	40,743
Comprehensive income (loss)														(20,252,862)
Ending Balance at Sep. 30, 2011														3,202,727
Ending Balance at Sep. 30, 2011														3,693,843	95,278	(2,038,733)	43,421,317	(38,275,135)	491,116
Ending Balance, Shares at Sep. 30, 2011															95,278,255
Beginning Balance (Pre-Adjusted Balance)
Comprehensive income (loss):
Net income (loss)														6,911,048
Ending Balance at Sep. 30, 2011														3,202,727
Ending Balance at Sep. 30, 2011														$ 3,693,843	$ 95,278	$ (2,038,733)	$ 43,421,317
Ending Balance, Shares at Sep. 30, 2011															95,278,255